title: Cellular immune responses in red blood cell alloimmunization.
abstract: In excess of 340 blood group antigens have now been described that vary between individuals. Thus, any unit of blood that is nonautologous represents a significant dose of alloantigen. Most blood group antigens are proteins, which differ by a single amino acid between donors and recipients. Approximately 1 out of every 70 individuals are transfused each year (in the United States alone), which leads to antibody responses to red blood cell (RBC) alloantigens in some transfusion recipients. When alloantibodies are formed, in many cases, RBCs expressing the antigen in question can no longer be safely transfused. However, despite chronic transfusion, only 3% to 10% of recipients (in general) mount an alloantibody response. In some disease states, rates of alloimmunization are much higher (eg, sickle cell disease). For patients who become alloimmunized to multiple antigens, ongoing transfusion therapy becomes increasingly difficult or, in some cases, impossible. While alloantibodies are the ultimate immune effector of humoral alloimmunization, the cellular underpinnings of the immune system that lead to ultimate alloantibody production are complex, including antigen consumption, antigen processing, antigen presentation, T-cell biology, and B-cell biology. Moreover, these cellular processes differ to some extent with regard to transfused RBCs as compared with other better-studied immune barriers (eg, infectious disease, vaccines, and solid organ transplantation). The current work focuses on illustrating the current paradigm of humoral immunity, with a specific focus on particulars of RBC alloimmunization and recent advances in the understanding thereof.
authors.affiliation: BloodworksNW Research Institute, Seattle, WA; and.|Division of Hematology, Departments of Laboratory Medicine and Internal Medicine, University of Washington School of Medicine, Seattle, WA.
authors.forename: James C
authors.initials: JC
authors.lastname: Zimring
authors.affiliation: BloodworksNW Research Institute, Seattle, WA; and.
authors.forename: Krystalyn E
authors.initials: KE
authors.lastname: Hudson
mesh_terms: D001402:B-Lymphocytes / Q000276:immunology / Q000378:metabolism; D001787:Blood Group Incompatibility / Q000097:blood / Q000453:epidemiology / Q000276:immunology*; D017707:Erythrocyte Transfusion / Q000009:adverse effects*; D004912:Erythrocytes / Q000276:immunology*; D006801:Humans; D007519:Isoantigens / Q000097:blood / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism
chemical_list: D007519:Isoantigens